Gilead Sciences (GILD) 93.79 $GILD
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Merck, J&J, Baxter Provide Healthy Dividend Stream
at Investor's Business Daily - Wed Jul 30, 6:01PM CDT
Drugmakers aim to help people live healthier lives, but they aren't immune to patent losses. Merck (MRK), which has recently faced a number of patent expirations, on Tuesday reported Q2 sales that slowed for an eighth quarter in a row. But earnings...
Final Glance: Biotechnology companies
AP - Wed Jul 30, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Jul 30, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Why Humana (HUM) Stock Is Declining Today
at The Street - Wed Jul 30, 10:58AM CDT
Humana (HUM) shares are down following the release of the company's second quarter earnings results.
Jim Cramer's Mad Dash: Good News for Regeneron
at The Street - Wed Jul 30, 9:45AM CDT
TheStreet's Jim Cramer says Regeneron has developed a breakthrough cholesterol drug while also receiving positive Phase III results for another treatment.
Early Glance: Biotechnology companies
AP - Wed Jul 30, 9:42AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Stock Market News for July 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 9:10AM CDT
Benchmarks settled in the red zone on Tuesday after a choppy session as the U.S. and the European Union expanded economic sanctions against Russia
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies
Business Wire - Wed Jul 30, 7:00AM CDT
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that it has entered into an agreement with Gilead Sciences, Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone's broadly neutralizing HIV-antibodies for therapeutic applications in HIV. These broadly neutralizing antibodies (bNAbs) were discovered in collaboration with the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute using Theraclone's proprietary I-STAR(TM) technology. The I-STAR technology allows for the rapid testing of tens of thousands of fully human antibodies to find those with exceptional biological functions and activities.
$1,000 Sovaldi now hepatitis treatment of choice
By RICARDO ALONSO-ZALDIVAR - AP - Tue Jul 29, 5:47PM CDT
WASHINGTON (AP) — The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.67% Yesterday
Comtex SmarTrend(R) - Tue Jul 29, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.60 to a high of $93.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $92.97 on volume of 14.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.67% Rise
Comtex SmarTrend(R) - Tue Jul 29, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.60 to a high of $93.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $92.97 on volume of 14.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Aetna Earnings Beat But Rising Medical Costs A Worry
at Investor's Business Daily - Tue Jul 29, 10:03AM CDT
Aetna gave its earnings guidance a booster shot following a strong second quarter aided by its acquisition of Coventry Health Care in 2013. The health insurer's earnings rose 11.2% to $1.69 a share, topping estimates for $1.60. Revenue jumped 25.3%...
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Imbruvica has been recommended for approval in the EU.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong
at The Street - Wed Jul 30, 6:55PM CDT
There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.
Merck, J&J, Baxter Provide Healthy Dividend Stream
at Investor's Business Daily - Wed Jul 30, 6:01PM CDT
Drugmakers aim to help people live healthier lives, but they aren't immune to patent losses. Merck (MRK), which has recently faced a number of patent expirations, on Tuesday reported Q2 sales that slowed for an eighth quarter in a row. But earnings...
Final Glance: Biotechnology companies
AP - Wed Jul 30, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Jul 30, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Why Humana (HUM) Stock Is Declining Today
at The Street - Wed Jul 30, 10:58AM CDT
Humana (HUM) shares are down following the release of the company's second quarter earnings results.
Jim Cramer's Mad Dash: Good News for Regeneron
at The Street - Wed Jul 30, 9:45AM CDT
TheStreet's Jim Cramer says Regeneron has developed a breakthrough cholesterol drug while also receiving positive Phase III results for another treatment.
Early Glance: Biotechnology companies
AP - Wed Jul 30, 9:42AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Stock Market News for July 30, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 30, 9:10AM CDT
Benchmarks settled in the red zone on Tuesday after a choppy session as the U.S. and the European Union expanded economic sanctions against Russia
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies
Business Wire - Wed Jul 30, 7:00AM CDT
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that it has entered into an agreement with Gilead Sciences, Inc., under which Gilead received an exclusive license to develop and commercialize products incorporating Theraclone's broadly neutralizing HIV-antibodies for therapeutic applications in HIV. These broadly neutralizing antibodies (bNAbs) were discovered in collaboration with the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute using Theraclone's proprietary I-STAR(TM) technology. The I-STAR technology allows for the rapid testing of tens of thousands of fully human antibodies to find those with exceptional biological functions and activities.
$1,000 Sovaldi now hepatitis treatment of choice
By RICARDO ALONSO-ZALDIVAR - AP - Tue Jul 29, 5:47PM CDT
WASHINGTON (AP) — The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.67% Yesterday
Comtex SmarTrend(R) - Tue Jul 29, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.60 to a high of $93.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $92.97 on volume of 14.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.67% Rise
Comtex SmarTrend(R) - Tue Jul 29, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.60 to a high of $93.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $92.97 on volume of 14.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Aetna Earnings Beat But Rising Medical Costs A Worry
at Investor's Business Daily - Tue Jul 29, 10:03AM CDT
Aetna gave its earnings guidance a booster shot following a strong second quarter aided by its acquisition of Coventry Health Care in 2013. The health insurer's earnings rose 11.2% to $1.69 a share, topping estimates for $1.60. Revenue jumped 25.3%...
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Imbruvica has been recommended for approval in the EU.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
